Federal Diagnostic Research Funds Will Head Off Future Epidemics – CBER
This article was originally published in The Gray Sheet
Executive Summary
CBER plans to create financial incentives for companies to develop diagnostic technologies for pathogens before the diseases become prevalent, according to center director Jesse Goodman
You may also be interested in...
FDLI Annual Conference In Brief
DES deemed model for FDA/CMS collaboration: CMS Administrator Mark McClellan, MD/PhD, is "very interested" in creating a faster pathway to market for promising new devices and drugs by better coordinating the approval and reimbursement processes at FDA and CMS. "A great model going forward for important new technologies" is mirroring "the work that we did jointly on drug-eluting stents where - with the manufacturers' support - our FDA staff was able to share the information we were using for the product approval decisions with CMS so that when FDA made its approval decision, the coverage codes and coverage for that treatment came right away," he explained at the Food & Drug Law Institute Annual Meeting April 15 in Washington, D.C...
FDLI Annual Conference In Brief
DES deemed model for FDA/CMS collaboration: CMS Administrator Mark McClellan, MD/PhD, is "very interested" in creating a faster pathway to market for promising new devices and drugs by better coordinating the approval and reimbursement processes at FDA and CMS. "A great model going forward for important new technologies" is mirroring "the work that we did jointly on drug-eluting stents where - with the manufacturers' support - our FDA staff was able to share the information we were using for the product approval decisions with CMS so that when FDA made its approval decision, the coverage codes and coverage for that treatment came right away," he explained at the Food & Drug Law Institute Annual Meeting April 15 in Washington, D.C...
CDC Assessing Accuracy Of SARS Diagnostis; Future Virus Mutations Expected
The Centers for Disease Control & Prevention has begun production and widespread distribution of reagents for the diagnosis of the Severe Acute Respiratory Syndrome (SARS) virus, Gen-Probe Chief Scientist Daniel Kacian MD/PhD explained during a Merrill Lynch conference call April 10